Related Experiment Video

Updated: May 24, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Testosterone improves cardiac function and alters angiotensin II receptors in isoproterenol-induced heart failure

Ning-Ning Kang1, Lu Fu, Jin Xu

  • 1Department of Cardiovascular Medicine, First Affiliated Hospital, Harbin Medical University, China.

Archives of Cardiovascular Diseases
|March 20, 2012
PubMed

Insights

Testosterone therapy may benefit heart failure by reducing cardiomyocyte apoptosis and fibrosis. Castration worsened heart failure, while testosterone replacement improved cardiac function and Bcl-2 protein expression.

Area of Science:

  • Cardiovascular Research
  • Endocrinology
  • Molecular Biology

Background:

  • The renin-angiotensin-aldosterone system is implicated in heart failure pathophysiology.
  • Testosterone's benefits in heart failure are reported, but mechanisms need elucidation.

Purpose of the Study:

  • To investigate the impact of castration and testosterone on cardiac function and angiotensin II receptor activity in a rat model of heart failure.

Main Methods:

  • Rats with isoproterenol-induced heart failure underwent castration, testosterone replacement, or sham procedures.
  • Cardiac function was assessed via echocardiography and hemodynamics.
  • Apoptosis, fibrosis, AT1/AT2 receptor mRNA, and Bcl-2 protein levels were quantified.

Main Results:

  • Castration exacerbated isoproterenol-induced cardiomyocyte apoptosis and fibrosis.
  • Testosterone replacement in castrated rats increased Bcl-2 protein and modulated AT2 receptor mRNA expression.

Conclusions:

  • Androgen therapy shows potential in managing heart failure pathophysiology.
  • Testosterone replacement may offer beneficial effects for heart failure treatment.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...